Clinical formulations
Some aspects of this disclosure provide clinical media that support viability, re-plating efficiency, and repopulation capacity of cells and tissues during storage for up to 48 hours or longer. The clinical media provided herein are also useful for clinical irrigation. Cell or tissue preparations comprising a cell population or tissue and a clinical medium as provided herein are also provided, as are methods for generating such preparations. Methods for using the clinical media and cell and tissue preparations provided herein, for example, for administering an effective amount of cells or tissue to a subject in need thereof, are also disclosed.
1. A solution comprising
about 0.1-1.2 mM CaCl 2 , about 0.05-5 mM MgCl 2 , about 1-2.5 mM KCl, about 0.5-2 mM sodium citrate, about 15-17 mM dextrose, and about 125-175 mM NaCl.
2. The solution of claim 1 , further comprising a polymer, wherein the polymer is present at a concentration of about 0.01-0.05% w/v.
3. The solution of claim 2 , wherein the polymer is hyaluronic acid or a salt or a solvate thereof.
4. The solution of claim 3 , wherein the polymer is sodium hyaluronate.
5. The solution of claim 2 , wherein the concentration of the polymer is about 0.05% w/v.
6. The solution of claim 1 , further comprising a population of cells.
7. The solution of claim 6 , wherein the population of cells is a population of retinal pigment epithelial (RPE) cells.
8. The solution of claim 1 , wherein the solution can be
(a) stored for at least 48 hours at 25° C. without measurable precipitation of solutes and/or measurable loss of the capability of the solution to support survival and viability of cells stored in the solution, and/or
(b) stored for at least 48 hours at 2-8° C. without measurable precipitation of solutes and/or measurable loss of the capability of the solution to support survival and viability of cells stored in the solution.
9. The solution of claim 1 , wherein the solution further comprises sodium acetate.
10. The solution of claim 1 , wherein the solution comprises
about 0.9 mM CaCl 2 , about 0.3 mM MgCl 2 , about 2 mM KCl, about 1.2 mM sodium citrate, about 15 mM dextrose, and about 145 mM NaCl.
11. A solution comprising
about 0.008-0.012% CaCl 2 dihydrate, about 0.0048-0.0072% MgCl 2 hexahydrate, about 0.012-0.018% KCl, about 0.028-0.042% sodium citrate dihydrate, about 0.23-0.35% dextrose, and about 0.68-1.02% NaCl.
12. The solution of claim 11 , wherein the solution comprises
about 0.01% CaCl 2 dihydrate, about 0.006% MgCl 2 hexahydrate, about 0.015% KCl, about 0.035% sodium citrate dihydrate, at least 0.25% dextrose, and about 0.85% NaCl.
13. The solution of claim 11 , further comprising a polymer, wherein the polymer is present at a concentration of about 0.01-0.05% w/v.
14. The solution of claim 13 , wherein the concentration of the polymer is about 0.05% w/v.
15. The solution of claim 13 , wherein the polymer is hyaluronic acid or a salt or a solvate thereof.
16. The solution of claim 15 , wherein the polymer is sodium hyaluronate.
17. The solution of claim 11 , wherein the solution further comprises sodium acetate.
18. The solution of claim 11 , further comprising a population of cells.
19. The solution of claim 18 , wherein the population of cells is a population of retinal pigment epithelial (RPE) cells.
20. The solution of claim 11 , wherein the solution can be
(a) stored for at least 48 hours at 25° C. without measurable precipitation of solutes and/or measurable loss of the capability of the solution to support survival and viability of cells stored in the solution, and/or
(b) stored for at least 48 hours at 2-8° C. without measurable precipitation of solutes and/or measurable loss of the capability of the solution to support survival and viability of cells stored in the solution.
21. A solution comprising
about 0.5-0.9 mM CaCl 2 , about 0.2-0.4 mM MgCl 2 , about 1.6-2.4 mM KCl, about 0.8-1.2 mM sodium citrate, about 13-19 mM dextrose, and about 116-174 mM NaCl.
22. The solution of claim 21 , further comprising a polymer, wherein the polymer is present at a concentration of about 0.01-0.05% w/v.
23. The solution of claim 22 , wherein the concentration of the polymer is about 0.05% w/v.
24. The solution of claim 22 , wherein the polymer is hyaluronic acid or a salt or a solvate thereof.
25. The solution of claim 24 , wherein the polymer is sodium hyaluronate.
26. The solution of claim 21 , wherein the solution further comprises sodium acetate.
27. The solution of claim 21 , further comprising a population of cells.
28. The solution of claim 27 , wherein the population of cells is a population of retinal pigment epithelial (RPE) cells.
29. The solution of claim 21 , wherein the solution can be
(a) stored for at least 48 hours at 25° C. without measurable precipitation of solutes and/or measurable loss of the capability of the solution to support survival and viability of cells stored in the solution, and/or
(b) stored for at least 48 hours at 2-8° C. without measurable precipitation of solutes and/or measurable loss of the capability of the solution to support survival and viability of cells stored in the solution.